These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 24743607)

  • 41. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
    Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
    Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Herrada J; Iyer RB; Atkinson EN; Sneige N; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 1997 Sep; 3(9):1565-9. PubMed ID: 9815844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Mátrai Z; Tóth L; Polgár C; Láng I; Gõdény M; Sinkovics I; Horváth Z; Bidlek M; Udvarhelyi N; Bartal A; Sávolt A; Ujhelyi M; Kásler M
    Magy Onkol; 2011 Jun; 55(2):73-84. PubMed ID: 21655472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
    Kuerer HM; Newman LA; Fornage BD; Dhingra K; Hunt KK; Buzdar AU; Ames FC; Ross MI; Feig BW; Hortobagyi GN; Singletary SE
    Ann Surg Oncol; 1998 Dec; 5(8):673-80. PubMed ID: 9869512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
    de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
    Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
    Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
    J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sentinel lymph node biopsy in patients with operable breast cancer treated with neoadjuvant chemotherapy.
    Rebollo-Aguirre AC; Gallego-Peinado M; Menjón-Beltrán S; García-García J; Pastor-Pons E; Chamorro-Santos CE; Ramos-Font C; Salamanca-Ballesteros A; Llamas-Elvira JM; Olea-Serrano N
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):117-23. PubMed ID: 21676504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial.
    Caudle AS; Yang WT; Mittendorf EA; Black DM; Hwang R; Hobbs B; Hunt KK; Krishnamurthy S; Kuerer HM
    JAMA Surg; 2015 Feb; 150(2):137-43. PubMed ID: 25517573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Neoadjuvant systemic therapy for breast cancer].
    Semiglazov VF
    Vopr Onkol; 2015; 61(2):162-8. PubMed ID: 26087591
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
    Kuerer HM; Newman LA; Smith TL; Ames FC; Hunt KK; Dhingra K; Theriault RL; Singh G; Binkley SM; Sneige N; Buchholz TA; Ross MI; McNeese MD; Buzdar AU; Hortobagyi GN; Singletary SE
    J Clin Oncol; 1999 Feb; 17(2):460-9. PubMed ID: 10080586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients Before Neoadjuvant Chemotherapy: A Preliminary Study.
    Kim EY; Byon WS; Lee KH; Yun JS; Park YL; Park CH; Youn IY; Choi SH; Choi YJ; Kook SH; Do SI
    World J Surg; 2018 Feb; 42(2):582-589. PubMed ID: 28808843
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors affecting lymph node yield in patients undergoing axillary node dissection for primary breast cancer: a single-institution review.
    Lee MC; Plews R; Rawal B; Kiluk JV; Loftus L; Laronga C
    Ann Surg Oncol; 2012 Jun; 19(6):1818-24. PubMed ID: 22203185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Complete axillary lymph node dissection for stage I-II carcinoma of the breast.
    Danforth DN; Findlay PA; McDonald HD; Lippman ME; Reichert CM; d'Angelo T; Gorrell CR; Gerber NL; Lichter AS; Rosenberg SA
    J Clin Oncol; 1986 May; 4(5):655-62. PubMed ID: 3701387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer patients with extra-axillary sentinel nodes only may be spared axillary lymph node dissection.
    van der Ploeg IM; Tanis PJ; Valdés Olmos RA; Kroon BB; Rutgers EJ; Nieweg OE
    Ann Surg Oncol; 2008 Nov; 15(11):3239-43. PubMed ID: 18773244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultrasound and fine needle aspiration cytology of axillary lymph nodes in breast cancer. To do or not to do?
    Leenders MW; Broeders M; Croese C; Richir MC; Go HL; Langenhorst BL; Meijer S; Schreurs WH
    Breast; 2012 Aug; 21(4):578-83. PubMed ID: 22717665
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Different strategies in marking axillary lymph nodes in breast cancer patients undergoing neoadjuvant medical treatment: a systematic review.
    Man V; Kwong A
    Breast Cancer Res Treat; 2021 Apr; 186(3):607-615. PubMed ID: 33611665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.